HomeFGEN • NASDAQ
add
FibroGen Inc
Nakaraang pagsara
$10.78
Sakop ng araw
$10.37 - $11.25
Sakop ng taon
$4.50 - $21.88
Market cap
41.96M USD
Average na Volume
31.75K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Financial Post
1 araw ang nakalipas
With the TSX in 'rarefied territory,' is it time to get defensive?
1.15%
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 1.35M | 35.07% |
Gastos sa pagpapatakbo | 7.06M | -52.66% |
Net na kita | -7.60M | 51.09% |
Net profit margin | -564.02 | 63.79% |
Kita sa bawat share | -1.88 | 53.00% |
EBITDA | -11.44M | 74.93% |
Aktuwal na % ng binabayarang buwis | 0.67% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 23.37M | -83.39% |
Kabuuang asset | 178.06M | -39.27% |
Kabuuang sagutin | 359.08M | -25.74% |
Kabuuang equity | -181.03M | — |
Natitirang share | 4.04M | — |
Presyo para makapag-book | -0.20 | — |
Return on assets | -16.98% | — |
Return on capital | 33.97% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -7.60M | 51.09% |
Cash mula sa mga operasyon | 12.68M | 131.81% |
Cash mula sa pag-invest | -13.00K | -100.02% |
Cash mula sa financing | -9.00K | -128.12% |
Net change in cash | 13.64M | -61.00% |
Malayang cash flow | -23.60M | 48.73% |
Tungkol
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative anemia and fibrosis therapies, the company’s reputation and market value declined sharply after 2020 following a series of late-stage trial failures, regulatory setbacks, and a data manipulation scandal involving its former chief medical officer. Wikipedia
Itinatag
Ene 1, 1993
Headquarters
Website
Mga Empleyado
225
